# US 2022/0196651 A1 · Multimers for reducing the interference of drugs that bind cd47 in serological assays

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0196651 A1
- Document ID: US20220196651A1
- Status: Published application
- Kind: A1
- Application number: 17/543,569
- Filed: 2021-12-06
- Published: 2022-06-23
- Earliest claimed: 2020-12-06
- Assignees: ALX Oncology Inc.
- Applicants: ALX Oncology Inc.
- Inventors: Jaume PONS; Bang Janet SIM; Amy Shaw-Ru CHEN; Emma Ruth SANGALANG
- Web page: https://patentgrep.com/patent/US20220196651A1

## CPC

- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/745: Blood coagulation or fibrinolysis factors
- C07K 16/2803: {against the immunoglobulin superfamily}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2440/28: PEGylation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are methods of reducing and/or preventing interference by a drug comprising (i) an antibody Fc region and (ii) a moiety that binds to human CD47 in serological assays.

## Claims

### Claim 1

A method of reducing drug interference in a serological assay using reagent red blood cells (RBC) or reagent platelets, said method comprising:
(a) adding a CD47 multimer that binds to the drug and blocks the drug from binding the reagent RBC or the reagent platelets to a plasma sample from a subject who has received treatment with the drug; and
(b) performing the serological assay of the plasma sample after step (a), using the reagent RBC or the reagent platelets,
wherein the drug comprises (i) a human antibody Fc region or variant thereof and (ii) a moiety that binds to human CD47, and
wherein the CD47 multimer comprises at least two CD47 polypeptide monomers.

### Claim at position 2

2-65. (canceled)

### Claim 66

A method of reducing drug interference in a serological assay using reagent red blood cells (RBC) or reagent platelets, said method comprising:
(a) adding an anti-SIRP multimer that binds to the drug and blocks the drug from binding the reagent RBC or the reagent platelets to a plasma sample from a subject who has received treatment with the drug; and
(b) performing the serological assay of the plasma sample after step (a), using the reagent RBC or the reagent platelets,
wherein the drug comprises (i) a human antibody Fc region or variant thereof and (ii) a moiety that binds to human CD47, and
wherein the anti-SIRP multimer comprises one or more anti-SIRP antibodies or drug-binding fragments thereof.

### Claim 67 (depends on 66)

The method of claim 66, wherein the anti-SIRP multimer comprises between 1 and 100 anti-SIRP antibodies or drug-binding fragments thereof.

### Claim 68 (depends on 66)

The method of claim 66, wherein the anti-SIRP multimer comprises an anti-SIRP antibody or drug-binding fragment thereof that binds to a wild type SIRPα, a SIRPα variant, a SIRPβ variant, a wild-type SIRPγ, a SIRPγ variant, or any two or more of the preceding.

### Claim 69 (depends on 66)

The method of claim 66, wherein the anti-SIRP multimer comprises an anti-SIRP antibody or drug-binding fragment thereof that comprises:
(a) a heavy chain variable domain (VH) that comprises SEQ ID NO: 46 and a light chain variable domain (VL) that comprises SEQ ID NO: 47;
(b) a heavy chain variable domain (VH) that comprises SEQ ID NO: 48 and a light chain variable domain (VL) that comprises SEQ ID NO: 49;
(c) a heavy chain variable domain (VH) that comprises SEQ ID NO: 50 and a light chain variable domain (VL) that comprises SEQ ID NO: 51;
(d) a heavy chain variable domain (VH) that comprises SEQ ID NO: 113 and a light chain variable domain (VL) that comprises SEQ ID NO: 114;
(e) a heavy chain variable domain (VH) that comprises SEQ ID NO: 115 and a light chain variable domain (VL) that comprises SEQ ID NO: 116; and/or
(f) a heavy chain variable domain (VH) that comprises SEQ ID NO: 133 and a light chain variable domain (VL) that comprises SEQ ID NO: 134.

### Claim 70 (depends on 66)

The method of claim 66 wherein the anti-SIRP multimer comprises a full length anti-SIRP antibody.

### Claim 71 (depends on 70)

The method of claim 70, wherein the anti-SIRP antibody comprises a murine Fc domain.

### Claim 72 (depends on 71)

The method of claim 71, wherein the murine Fc domain comprises an amino acid sequence set forth in any one of SEQ ID NOs: 81-83.

### Claim 73 (depends on 70)

The method of claim 70, wherein the anti-SIRP antibody comprises:
(a) a heavy chain that comprises SEQ ID NO: 117 and a light chain that comprises SEQ ID NO: 118;
(b) a heavy chain that comprises SEQ ID NO: 119 and a light chain that comprises SEQ ID NO: 118;
(c) a heavy chain that comprises SEQ ID NO: 120 and a light chain that comprises SEQ ID NO: 121; or
(d) a heavy chain that comprises SEQ ID NO: 122 and a light chain that comprises SEQ ID NO: 121.

### Claim 74 (depends on 66)

The method of claim 66, wherein the drug-binding fragment of the anti-SIRP antibody is a Fab, a Fab′, an F(ab′)2, a Fab′-SH, an Fv, a diabody, a one-armed antibody, an scFv, an scFv-Fc, a single domain antibody, or a single heavy chain antibody.

### Claim 75 (depends on 74)

The method of claim 74, wherein the drug binding fragment comprises a F(ab′)2, and wherein the F(ab′)2 comprises SEQ ID NOs: 131 and 132.

### Claim 76 (depends on 66)

The method of claim 66, wherein the anti-SIRP antibody or drug-binding fragment thereof comprises an epitope tag or a ligand.

### Claim 77 (depends on 76)

The method of claim 76, wherein the epitope tag comprises any one of SEQ ID NOs: 7-32 and 126, or wherein the ligand comprises biotin.

### Claim 78 (depends on 76)

The method of claim 76, wherein the epitope tag comprises HHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 135) or GSGSHHHHHHGLNDIFEAQKIEWHE (SEQ ID NO: 126).

### Claim 79 (depends on 66)

The method of claim 66, wherein the one or more anti-SIRP antibodies or drug-binding fragments thereof are attached to a solid support.

### Claim 80

(canceled)

### Claim 81 (depends on 79)

The method of claim 79, wherein each of the one or more anti-SIRP antibodies or drug-binding fragments thereof comprises an epitope tag or a ligand, wherein a capture agent that specifically binds the epitope tag or ligand is immobilized on the solid support, and wherein the anti-SIRP antibodies or drug-binding fragments thereof are attached to the solid support by the specific binding of the epitope tag or ligand by the capture agent.

### Claim 82 (depends on 81)

The method of claim 81, wherein the ligand is biotin and wherein the capture agent is streptavidin.

### Claim 83 (depends on 66)

The method of claim 66, wherein the anti-SIRP multimer comprises a streptavidin or avidin bound to 2, 3, or 4 biotinylated anti-SIRP antibodies or fragments thereof.

### Claim 84 (depends on 82)

The method of claim 82, wherein the anti-SIRP multimer comprises the streptavidin or the avidin bound to 2, 3, or 4 biotinylated F(ab′)2 fragments, wherein 2 or more of the biotinylated F(ab′)2 fragments comprise SEQ ID NOs: 131 and 132.

### Claim 85 (depends on 66)

The method of claim 66, wherein the anti-SIRP multimer is a homomultimer or a heteromultimer.

### Claim at position 23

86-87. (canceled)

### Claim 88 (depends on 66)

The method of claim 66, wherein the moiety of the drug that binds to human CD47 comprises:
(a) a wild type SIRPα,
(b) a SIRPα variant that comprises one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), and/or C-terminal extension(s) relative to the wild type SIRPα,
(c) a fragment of the wild type SIRPα that comprises an extracellular domain of the wild type SIRPα, or
(d) a fragment of the SIRPα variant that comprises an extracellular domain of the SIRPα variant.

### Claim at position 25

89-90. (canceled)

### Claim 91 (depends on 66)

The method of claim 66, wherein the moiety of the drug that binds to human CD47 comprises:
(a) a wild type SIRPγ,
(b) a SIRPγ variant that comprises one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), and/or C-terminal extension(s) relative to the wild type SIRPγ,
(c) a fragment of the wild type SIRPγ that comprises an extracellular domain of the wild type SIRPγ, or
(d) a fragment of the SIRPγ variant that comprises an extracellular domain of the SIRPγ variant.

### Claim at position 27

92-93. (canceled)

### Claim 94 (depends on 66)

The method of claim 66, wherein the moiety of the drug that binds to human CD47 comprises:
(a) a SIRPβ variant that comprises one or more amino acid substitution(s), insertion(s), deletion(s), N-terminal extension(s), C-terminal extension(s), or any combination of the preceding, relative to the wild type SIRPβ, or
(b) a fragment of the SIRPβ variant that comprises an extracellular domain of the SIRPβ variant.

### Claim at position 29

95-96. (canceled)

### Claim 97 (depends on 66)

The method of claim 66, wherein the antibody Fc region of the drug is a human IgG Fc region, and wherein the human IgG Fc region is IgG1, IgG2, IgG4, or a variant of any one of the preceding.

### Claim 98

(canceled)

### Claim 99 (depends on 66)

The method of claim 66, wherein the serological assay is:
(a) an ABO/Rh typing assay,
(b) an immediate spin (IS) assay,
(c) a direct antiglobulin (DAT) assay using a polyspecific reagent that detects IgG and complement C3,
(d) a direct antiglobulin (DAT) assay using a monospecific reagent that detects complement C3,
(e) a PEG-enhanced serological assay,
(f) an eluate test that is performed following a DAT assay,
(g) a tube assay or a solid phase red cell assay (SPRCA),
(h) a gel card assay, or
(i) a solid phase assay.

### Claim at position 33

100-170. (canceled)

### Claim 171

An anti-SIRP multimer comprising one or more anti-SIRP antibodies or drug-binding fragments thereof.

### Claim at position 35

172-191. (canceled)
